284 related articles for article (PubMed ID: 17255261)
1. Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer.
Mehra N; Penning M; Maas J; van Daal N; Giles RH; Voest EE
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):421-6. PubMed ID: 17255261
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy.
Ellinger J; Müller SC; Wernert N; von Ruecker A; Bastian PJ
BJU Int; 2008 Aug; 102(5):628-32. PubMed ID: 18410441
[TBL] [Abstract][Full Text] [Related]
3. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
[TBL] [Abstract][Full Text] [Related]
4. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
6. Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker.
Ellinger J; Albers P; Müller SC; von Ruecker A; Bastian PJ
BJU Int; 2009 Jul; 104(1):48-52. PubMed ID: 19154496
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
Taplin ME; George DJ; Halabi S; Sanford B; Febbo PG; Hennessy KT; Mihos CG; Vogelzang NJ; Small EJ; Kantoff PW
Urology; 2005 Aug; 66(2):386-91. PubMed ID: 16098367
[TBL] [Abstract][Full Text] [Related]
9. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
10. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2009 Mar; 181(3):1091-7. PubMed ID: 19150091
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
13. Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?
Denham JW; Steigler A; Wilcox C; Lamb DS; Joseph D; Atkinson C; Tai KH; Spry NA; Gleeson PS; D'Este C
Cancer; 2009 Oct; 115(19):4477-87. PubMed ID: 19691097
[TBL] [Abstract][Full Text] [Related]
14. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.
Ellinger J; Müller DC; Müller SC; Hauser S; Heukamp LC; von Ruecker A; Bastian PJ; Walgenbach-Brunagel G
Urol Oncol; 2012; 30(4):509-15. PubMed ID: 20870429
[TBL] [Abstract][Full Text] [Related]
15. Dihydrotestosterone levels and survival in screening-detected prostate cancer: a 15-yr follow-up study.
Kjellman A; Akre O; Norming U; Törnblom M; Gustafsson O
Eur Urol; 2008 Jan; 53(1):106-11. PubMed ID: 17482753
[TBL] [Abstract][Full Text] [Related]
16. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer.
Margel D; Tal R; Baniel J
J Urol; 2007 Dec; 178(6):2297-300; discussion 2300-1. PubMed ID: 17936837
[TBL] [Abstract][Full Text] [Related]
17. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence.
Seligson DB; Hongo F; Huerta-Yepez S; Mizutani Y; Miki T; Yu H; Horvath S; Chia D; Goodglick L; Bonavida B
Clin Cancer Res; 2007 Oct; 13(20):6056-63. PubMed ID: 17947468
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
[TBL] [Abstract][Full Text] [Related]
19. Short- and long-term mortality with localized prostate cancer.
Merglen A; Schmidlin F; Fioretta G; Verkooijen HM; Rapiti E; Zanetti R; Miralbell R; Bouchardy C
Arch Intern Med; 2007 Oct; 167(18):1944-50. PubMed ID: 17923593
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
